Table 1

Baseline and follow-up demographic, clinical, and survival characteristics
Patients with HCV and ALD (Cases) Patients with HCV and without ALD (Controls) P-value
N 1193 1193
Baseline
Age at index date
Mean 48.6 49.0 0.268
SD 8.6 8.7
Median 49.0 49.0
<35 5.0% 4.4%
35-44 22.8% 21.2%
45-54 50.3% 50.6%
55+ 21.9% 23.8%
Male (%) 54.6% 54.6% 1.000
Race
White 54.1% 54.1% 1.000
Black 23.3% 23.3% 1.000
Hispanic 9.8% 9.8% 1.000
Other 12.8% 12.8% 1.000
Charlson score1
Mean 3.1 2.3 < .001
SD 3.2 2.7
Median 2.0 1.0
Follow-Up
Duration of follow-up (days)
Mean 277 366 < .001
SD 135 8
Median 366 366
Survival
Died during evaluation period (%) 35.1% 0.8% < .001
Selected non-ALD-related diagnoses (%)
Alcoholic cirrhosis 28.8% 1.1% < .001
Diabetes 24.8% 19.8% 0.004
Gastrointestinal bleeding 20.2% 3.6% < .001
HBV 9.7% 2.9% < .001
HIV 25.2% 23.7% 0.418
Other sequelae of chronic liver disease 10.5% 0.3% < .001
Acute Renal failure 13.1% 2.2% < .001
Unspecified disorder of the liver 11.2% 1.8% < .001
Selected ALD-related diagnoses (%)
Ascites 54.5% 0.0% < .001
Esophageal varices without bleeding 11.2% 0.0% < .001
Hepatic coma (encephalopathy) 19.4% 0.0% < .001
Portal hypertension 11.7% 0.0% < .001

Source: Florida Medicaid database: claims with dates of service between July 1, 1998 and June 30, 2008.

Note: Comparison patients were matched based on 5-year age groupings, sex, and race to cases.

1T-tests were used to evaluate differences in mean age and Charlson score, while Wilcoxon tests were used for duration of follow-up. The Fisher Exact 2-tailed test was used for comparisons of proportions.

2Race/ethnicity was patient-identified; with "Other" race/ethnicity including American Indian, Asian, and others.

3Charlson score excludes HCC, 'Mild Liver Disease' and 'Liver Disease' comorbidities.

4Significance testing was not performed on ALD-related diagnoses as the comparison cohort could not have any of these diagnoses in baseline or follow-up by definition. These diagnoses were based on all inpatient and outpatient diagnoses observed over the follow-up period: ALD advanced liver disease, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus.

Menzin et al.

Menzin et al. BMC Health Services Research 2012 12:459   doi:10.1186/1472-6963-12-459

Open Data